Article Information
History
- February 21, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jiaze Tang1,2,3,*,
- Anji Ju1,2,3,*,
- Boya Li1,2,3,*,
- Shaosen Zhang1,2,3,
- Yuanchao Gong1,2,3,
- Boyuan Ma1,2,3,
- Yi Jiang1,2,3,
- Hongyi Liu1,2,3,
- Yan Fu1,2,3,† and
- Yongzhang Luo1,2,3,†,‡
- 1The National Engineering Laboratory for Anti-Tumor Protein Therapeutics, Tsinghua University, Beijing, China
- 2Beijing Key Laboratory for Protein Therapeutics, Tsinghua University, Beijing, China
- 3Cancer Biology Laboratory, School of Life Sciences, Tsinghua University, Beijing, China
- ↵†Contact Information: Corresponding author. Email: yluo{at}tsinghua.edu.cn (Yongzhang Luo); fuyan{at}tsinghua.edu.cn (Yan Fu).
↵* These authors contributed equally to this work.
Posted February 21, 2021.
